NCT02970318 2026-05-11A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLAcerta Pharma BVPhase 3 Active not recruiting310 enrolled 18 charts 1 FDA
NCT04666038 2026-04-24BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA